Adenosine phosphate - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Included in the formulation

АТХ:

C.01.E.B.10 Adenosine

Pharmacodynamics:

Adenosine phosphate is a part of the most important coenzymes-regulators of oxidation-reduction processes in cells and tissues of the body.It is also a fragment of ATP responsible for endothermic reactions (muscle activity and protein synthesis). AMP indirectly regulates the formation of aminolevulinic acid and its transformation into protoporphyrin, plays a role in the normalization of the synthesis of porphyrins.

It improves tissue metabolism, macro- and microcirculation, has a vasodilating and antiplatelet effect, thereby stimulating regeneration processes.

According to some studies adenosine phosphate improves the condition with psoriasis and diabetic retinopathy. Accelerates the healing of ulcers with peptic ulcer, without violating the secretory and acid-forming functions of the organs of the gastrointestinal tract.

Pharmacokinetics:

Biotransformation occurs in erythrocytes, vascular endothelial cells to inactive inosine and adenosine monophosphate. Eliminated kidneys in the form of inactive metabolites. The half-life is 10-30 seconds.

Indications:

- Suppression of paroxysmal supraventricular tachycardia.

- As an auxiliary diagnostic tool (carrying out two-dimensional echocardiography, scintigraphy, determining the location of AV blockade).

- Acute intermittent porphyria, polyneuritic syndrome (due to lead poisoning).

- Acute thrombosis of superficial and deep veins of extremities, acute occlusion of arteries (in the stage of conservative treatment and in the postoperative period), obliterating endarteritis, venectomy (pre- and postoperative period), chronic venous insufficiency, thrombophlebitis, secondary vascular syndromes caused by spine injury.

- Post-burn complications: non-healing wounds, trophic after-burn ulcers.

- Hereditary diseases of the central nervous system: Konovalov-Wilson's disease), multiple sclerosis.

- Chronic hepatitis, cirrhosis, duodenal ulcer.

- Chronic heart failure.

- Asthenic syndrome.

- Psoriasis and diabetic retinopathy.

ICD-10

IV.E70-E90.E80.2 Other porphyria

IV.E70-E90.E83.0 Disorders of copper exchange

VI.G35-G37.G35 Multiple sclerosis

V.F40-F48.F48.0 Neurasthenia

IX.I20-I25.I20 Angina pectoris [angina pectoris]

IX.I80-I89.I82 Embolism and thrombosis of other veins

IX.I70-I79.I74.9 Embolism and thrombosis of unspecified arteries

VII.H30-H36.H36.0 * Diabetic retinopathy (E10-E14 + with common fourth sign .3)

IX.I30-I52.I50.0 Congestive heart failure

IX.I80-I89.I80 Phlebitis and thrombophlebitis

IX.I80-I89.I87.2 Venous insufficiency (chronic) (peripheral)

XII.L40-L45.L40 Psoriasis

XI.K20-K31.K26 Duodenal ulcer

XI.K20-K31.K25 Stomach ulcer

XI.K70-K77.K74 Fibrosis and cirrhosis of the liver

XIII.M70-M79.M79.2 Neuralgia and neuritis, unspecified

XIX.T08-T14.T14.1 Open wound of unspecified area of the body

Contraindications:

Individual intolerance.

AV-blockade II-III degree (except for patients with an artificial pacemaker).

Ventricular tachycardia.

Carefully:No data.

Pregnancy and lactation:

Due to rapid metabolism it does not have any negative effect on the fetus, nor does it enter breast milk and can not affect the baby when breastfeeding.

Dosing and Administration:

Suppression of paroxysmal supraventricular tachycardia: intravenously bolus (within 1-2 seconds) at a dose of 6 mg. If there is no effect, 12 mg are administered intravenously bolus for 1-2 minutes, if necessary repeat in the indicated dose.

As an auxiliary diagnostic tool: intravenous infusion at a dose of 140 μg / kg / min for 6 minutes (total dose - 840 μg / kg). In patients with a high risk of adverse effects, infusion begins with lower doses (from 50 μg / kg / min). The maximum single dose is 12 mg.

Single doses for oral administration - 25-50 mg, with a / m introduction - 20-60 mg. The multiplicity and duration of application depend on the readings.

- In ophthalmic practice, application in the form of retrobulbar injections is possible.

Side effects:

The cardiovascular system: tachycardia, noise in the head, arrhythmias.

Nervous system: dizziness and headache, migraine attacks.

Digestive system: nausea, pain in the abdomen.

Respiratory system: dyspnea, attacks of bronchial asthma.

Others: allergic reactions are possible.

Overdose:No data.

Interaction:

Dipyridamole potentiates the effects of adenosine.

Carbamazepine can aggravate the blockade caused by adenosine.

When used simultaneously with xanthines during the conduct of two-dimensional echocardiography, scintigraphy may be a violation of the results of the study.

Special instructions:

In / in the introduction is possible only in the hospital with constant monitoring of the heart rate. Introduction through the central veins reduces the risk of side effects.

Adenosine phosphate is not prescribed for fibrillation, atrial flutter, atrial extrasystole due to inefficiency.

Instructions

Adenosine phosphate (Adenosini phosphas)